Exosomal lncRNA RAMP2-AS1 Derived from Chondrosarcoma Cells Promotes Angiogenesis Through miR-2355-5p/VEGFR2 Axis
Authors:
Open Access
- 1 April 2020
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 3291-3301
Abstract
Objective: Exosomes derived from cancer cells can alter the microenvironment and enhance cancer malignancy through the regulation of peripheral cell functions. The present study focused on the crosstalk between chondrosarcoma cells and human umbilical vein endothelial cells (HUVECs) mediated by exosomes derived from chondrosarcoma cells and aimed to explore the potential molecular mechanism. Materials and Methods: Chondrosarcoma cell-derived exosomes were isolated and characterized. Cell proliferation assay, tube formation assay and transwell migration assay were performed to characterize the effects of exosomes on HUVECs. The lncRNA microarray was used to select differentially expressed lncRNAs in HUVECs treated with or without exosomes. Serum samples of patients with chondrosarcoma were collected to analyze the correlation between the RAMP2-AS1 level and the clinicopathological features. Online databases were used to predict the target microRNA of RAMP2-AS1. Dual luciferase reporter assay, Western blotting and qRT-PCR assays were performed to verify the interactions among RAMP2-AS1, miR-2355-5p and VEGFR2. Rescue experiments were conducted to validate the existence of the RAMP2-AS1/miR-2355-5p/VEGFR2 axis. Results: The exosomes secreted by chondrosarcoma cells could enhance HUVECs proliferation, migration and tube formation. LncRNA microarray analysis revealed that exosomes carried lncRNA RAMP2-AS1, and further verification showed that the level of RAMP2-AS1 was increased in the serum of chondrosarcoma patients and was closely related to local invasiveness, distant metastasis and poor prognosis. Subsequent experiments demonstrated that RAMP2-AS1 knockdown could partly abrogate the promoting effects on angiogenesis induced by exosomes derived from chondrosarcoma cells. Moreover, dual luciferase reporter assay and rescue experiments suggested that the RAMP2-AS1/miR-2355-5p/VEGFR2 axis was responsible for exosome-induced angiogenesis of HUVECs. Conclusion: Chondrosarcoma cell-derived exosomes carry lncRNA RAMP2-AS1, which acts as a ceRNA of miR-2355-5p to regulate VEGFR2 expression, thereby positively regulating the angiogenic ability of HUVECs. Thus, exosomal RAMP2-AS1 has the potential as a novel biomarker and therapeutic target for chondrosarcoma.Keywords
This publication has 26 references indexed in Scilit:
- Molecular oncogenesis of chondrosarcoma: impact for targeted treatmentCurrent Opinion in Oncology, 2016
- The biology and function of exosomes in cancerJournal of Clinical Investigation, 2016
- Anti-angiogenic therapy, a new player in the field of sarcoma treatmentCritical Reviews in Oncology/Hematology, 2014
- Chondrosarcoma of Bone2014
- VEGFA and tumour angiogenesisJournal of Internal Medicine, 2013
- Angiopoietins in angiogenesisCancer Letters, 2013
- Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseasesThe Journal of Biochemistry, 2012
- Angiogenesis and anti-angiogenesis in hepatocellular carcinomaCancer Treatment Reviews, 2006
- Differential expression of VEGF isoforms and VEGF receptors in cartilaginous tumors.2005
- Role of angiogenesis in tumor growth and metastasisSeminars in Oncology, 2002